**Appendix Table D117. Adverse effects with onabotulinumtoxin A vs. placebo for migraine prevention in adults (results from randomized controlled clinical trials were pooled with Bayesian odds ratios and maximum likelihood absolute risk difference)**

| **Adverse Effect** | **Dose and Weeks of Treatment** | **Reference****Risk of Bias** | **Events/****Randomized with Drug** | **Events/****Randomized with Placebo** | **Bayesian Odds Ratio (Median, 2.5 and 97.5% CrI)** | **Weight** | **Absolute Risk Difference, Maximum Likelihood Method (95% CI)** | **Weight** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Any adverse effect | 6U 12 weeks | Saper, 20074Low | 8/45 | 3/11 | 0.6 (0.1 to 2.7) | 0.027 | 0.04 (-0.16 to 0.24) | 0.03 |
| Any adverse effect | 7.5U 16 weeks | Elkind, 20067Low | 52/105 | 17/36 | 1.1 (0.5 to 2.3) | 0.058 | 0.07 (-0.09 to 0.22) | 0.045 |
| Any adverse effect | 9U 12 weeks | Saper, 20074Low | 11/49 | 3/12 | 0.9 (0.2 to 3.8) | 0.029 | 0.07 (-0.13 to 0.26) | 0.031 |
| Any adverse effect | 10U 12 weeks | Saper, 20074Low | 9/44 | 3/11 | 6.2 (0.3 to 114.2) | 0.009 | 0.19 (0.05 to 0.33) | 0.049 |
| Any adverse effect | 25U 16 weeks | Elkind, 20067Low | 47/101 | 16/34 | 1.0 (0.4 to 2.1) | 0.056 | 0.05 (-0.11 to 0.21) | 0.044 |
| Any adverse effect | 25U 12 weeks | Saper, 20074Low | 17/49 | 3/12 | 1.6 (0.4 to 6.7) | 0.03 | 0.13 (-0.07 to 0.32) | 0.03 |
| Any adverse effect | 50U 16 weeks | Elkind, 20067Low | 60/106 | 17/36 | 1.5 (0.7 to 3.1) | 0.058 | 0.11 (-0.04 to 0.27) | 0.045 |
| Any adverse effect | 75 U 24 weeks | Silberstein, 200511Low | 97/174 | 13/59 | 4.5 (2.2 to 8.8) | 0.062 | 0.30 (0.19 to 0.42) | 0.057 |
| Any adverse effect | 80U 12 weeks | Petri\*, 20099High | 4/32 | 5/32 | 0.8 (0.2 to 3.2) | 0.03 | 0.02 (-0.12 to 0.17) | 0.048 |
| Any adverse effect | 139U 12 weeks | Cady, 200813Low | 0/40 | 0/19 | 0.5 (0.0 to 25.2) | 0.005 | 0.01 (-0.06 to 0.09) | 0.067 |
| Any adverse effect | 150 U 24 weeks | Silberstein, 200511Low | 92/168 | 12/57 | 4.5 (2.2 to 9.2) | 0.061 | 0.30 (0.19 to 0.42) | 0.056 |
| Any adverse effect | 105U-260U (“Follow-the-pain” approach) 24 (3 injections at day 0, day 90, and day 180) weeks | Mathew, 200510Risk of bias Low | 88/173 | 42/182 | 3.5 (2.2 to 5.4) | 0.075 | 0.26 (0.17 to 0.36) | 0.063 |
| Any adverse effect | 155U-195U [Follow-the-pain strategy] 24 (two injections over the course: week 1, week 12; open label 3 injections: week 24, 36, 48) weeks | Aurora, 20101Medium | 86/341 | 39/338 | 2.6 (1.7 to 3.9) | 0.078 | 0.14 (0.08 to 0.19) | 0.07 |
| Any adverse effect | 155U-195U [Follow-the-Pain strategy] 24 (three injections over the course: week 1, week 12, week 24) weeks | Diener, 20102Low | 116/347 | 49/358 | 3.2 (2.2 to 4.6) | 0.08 | 0.20 (0.14 to 0.26) | 0.069 |
| Any adverse effect | 155U-195U [Follow-the-Pain strategy] 24 (2 injections over the course: week 1, week 12; open label 3 injections: week 24, 36, 48) weeks | Aurora, 20101Medium | 203/341 | 156/338 | 1.7 (1.3 to 2.3) | 0.083 | 0.14 (0.06 to 0.21) | 0.067 |
| Any adverse effect | 110 U to 260 U per treatment weeks | Aurora, 200715Medium | 113/187 | 39/182 | 5.6 (3.5 to 8.9) | 0.075 | 0.37 (0.28 to 0.45) | 0.064 |
| Any adverse effect | 155U-195U [Follow-the-Pain strategy] 24 (3 injections over the course: week 1, week 12, week 24) weeks | Diener, 20102Low | 226/347 | 202/358 | 1.4 (1.1 to 2.0) | 0.083 | 0.09 (0.02 to 0.16) | 0.068 |
| Any adverse effect | 210U 12 (one time injection) weeks | Petri\*, 20099High | 12/32 | 6/32 | 2.6 (0.8 to 8.1) | 0.039 | 0.18 (0.01 to 0.35) | 0.04 |
| Any adverse effect | 225 U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 119/182 | 13/62 | 7.1 (3.6 to 14.1) | 0.062 | 0.40 (0.28 to 0.51) | 0.058 |
| **Any adverse effect** | **Pooled** |  | **1360/2863** | **637/2168** | **2.2 (1.5 to 3.0)** | **1** | **0.16 (0.09 to 0.23)** | **1** |
| Back pain | 75 U 24 (3 injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 3/174 | 0/59 | 2.4 (0.1 to 47.7) | 0.177 | 0.02 (-0.01 to 0.04) | 0.205 |
| Back pain | 100U 16 weeks | Freitag, 20085Low | 0/20 | 1/21 | 0.3 (0.0 to 8.7) | 0.148 | 0.01 (-0.02 to 0.04) | 0.013 |
| Back pain | 150 U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 4/168 | 0/57 | 3.1 (0.2 to 59.3) | 0.182 | 0.02 (0.00 to 0.04) | 0.17 |
| Back pain | 110 U to 260 U per treatment weeks | Aurora, 200715Medium | 3/187 | 1/182 | 3.0 (0.3 to 28.6) | 0.304 | 0.01 (-0.01 to 0.03) | 0.448 |
| Back pain | 225 U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 6/182 | 0/62 | 4.6 (0.3 to 82.9) | 0.188 | 0.02 (0.00 to 0.05) | 0.164 |
| **Back pain** | **All doses** | **Pooled**  | **16/731** | **2/381** | **4.9 (1.2 to 35.7)** | **1** | **0.02 (0.00 to 0.04)** | **1** |
| Discontinuations related to AE | 155U-195U [Follow-the-Pain strategy] 24 (three injections over the course: week 1, week 12, week 24) weeks | Diener, 20102Low | 12/347 | 5/358 | 2.5 (0.9 to 7.3) | 0.587 | 0.03 (0.01 to 0.04) | 0.512 |
| Discontinuations related to AE | 155U-195U [Follow-the-Pain strategy] 24 (2 injections over the course: week 1, week 12; open label 3 injections: week 24, 36, 48) weeks | Aurora, 20101Medium | 14/341 | 3/338 | 4.8 (1.4 to 16.8) | 0.413 | 0.03 (0.02 to 0.04) | 0.488 |
| **Discontinua­tions related to adverse effects** | **All doses** | **Pooled** | **26/688** | **8/696** | **3.5 (1.2 to 10.9)** | **1** | **0.03 (0.01 to 0.05)** | **1** |
| Dizziness | 100U 16 weeks | Freitag, 20085Low | 0/20 | 1/21 | 0.3 (0.0 to 8.7) | 0.156 | 0.00 (-0.05 to 0.05) | 0.031 |
| Dizziness | 120U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 2/43 | 0/21 | 2.6 (0.1 to 56.4) | 0.174 | 0.02 (-0.03 to 0.06) | 0.053 |
| Dizziness | 105U-260U (“Follow-the-pain” approach) 24 weeks | Mathew, 200510Low | 1/173 | 3/182 | 0.3 (0.0 to 3.4) | 0.32 | -0.01(-0.03 to 0.01) | 0.437 |
| Dizziness | 110 U to 260 U per treatment weeks | Aurora, 200715Medium | 4/187 | 0/182 | 9.0(0.5 to 167.5) | 0.193 | 0.02 (0.00 to 0.04) | 0.413 |
| Dizziness | 240U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 1/43 | 0/21 | 1.5 (0.1 to 38.8) | 0.157 | 0.01 (-0.03 to 0.06) | 0.066 |
| Dizziness | All doses | Pooled | 8/466 | 4/427 | 1.8 (0.5 to 8.0) | 1 | 0.01 (-0.02 to 0.04) | 1 |
| Dysphagia | 75 U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 3/174 | 0/59 | 2.4 (0.1 to 47.7) | 0.24 | 0.03 (0.00 to 0.05) | 0.258 |
| Dysphagia | 150 U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 5/168 | 0/57 | 3.9 (0.2 to 71.1) | 0.251 | 0.03 (0.01 to 0.05) | 0.193 |
| Dysphagia | 105U-260U (“Follow-the-pain” approach) 24 (3 injections at day 0, day 90, and day 180) weeks | Mathew, 20510Low | 4/173 | 0/182 | 9.7(0.5 to 181.3) | 0.248 | 0.03 (0.01 to 0.05) | 0.404 |
| Dysphagia | 225 U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 11/182 | 0/62 | 8.4(0.5 to 144.4) | 0.262 | 0.04 (0.02 to 0.07) | 0.144 |
| **Dysphagia** | **All doses** | **Pooled** | **23/697** | **1/360** |  |  | **0.03 (0.01 to 0.05)** | **1** |
| Eyelid edema | 7.5U 16 weeks | Elkind, 20067Low | 1/105 | 0/36 | 1.0 (0.0 to 26.3) | 0.16 | 0.01 (-0.03 to 0.05) | 0.217 |
| Eyelid edema | 25U 16 weeks | Elkind, 20067Low | 0/101 | 0/34 | 0.3 (0.0 to 17.5) | 0.121 | 0.00 (-0.03 to 0.04) | 0.225 |
| Eyelid edema | 50U 16 weeks | Elkind, 20067Low | 7/106 | 0/36 | 5.5 (0.3 to 98.8) | 0.184 | 0.05 (0.00 to 0.09) | 0.16 |
| Eyelid edema | 120U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 1/43 | 1/21 | 0.5 (0.0 to 8.0) | 0.189 | 0.00 (-0.06 to 0.06) | 0.081 |
| Eyelid edema | 110 U to 260 U per treatment weeks | Aurora, 200715Medium | 12/187 | 0/182 | 26.0(1.5 to 442.4) | 0.188 | 0.06 (0.02 to 0.09) | 0.245 |
| Eyelid edema | 240U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 0/43 | 1/21 | 0.2 (0.0 to 4.0) | 0.159 | 0.00 (-0.06 to 0.06) | 0.072 |
| Eyelid edema | All doses | Pooled | 21/585 | 1/330 | 5.5 (0.8 to 62.0) | 1 | 0.02 (-0.02 to 0.06) | 1 |
| Headache | 6U 12 weeks | Saper, 20074Low | 2/45 | 0/11 | 1.3 (0.1 to 29.5) | 0.019 | 0.01 (-0.05 to 0.06) | 0.022 |
| Headache | 7.5U 16 weeks | Elkind, 20067Low | 1/105 | 1/36 | 0.3 (0.0 to 5.5) | 0.023 | -0.01(-0.05 to 0.03) | 0.118 |
| Headache | 9U 12 weeks | Saper, 20074Low | 0/49 | 1/12 | 0.1 (0.0 to 2.0) | 0.017 | -0.01(-0.07 to 0.05) | 0.012 |
| Headache | 10U 12 weeks | Saper, 20074Low | 1/44 | 0/11 | 0.8 (0.0 to 20.8) | 0.017 | 0.00 (-0.05 to 0.06) | 0.025 |
| Headache | 25U 12 weeks | Saper, 20074Low | 3/49 | 1/12 | 0.7 (0.1 to 7.6) | 0.032 | 0.00 (-0.06 to 0.06) | 0.013 |
| Headache | 25U 16 weeks | Elkind, 20067Low | 2/101 | 1/34 | 0.7 (0.1 to 7.6) | 0.031 | -0.01(-0.05 to 0.04) | 0.096 |
| Headache | 50U 16 weeks | Elkind, 20067Low | 8/106 | 1/36 | 2.9 (0.3 to 23.7) | 0.04 | 0.02 (-0.03 to 0.07) | 0.07 |
| Headache | 75 U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 7/174 | 3/59 | 0.8 (0.2 to 3.1) | 0.094 | -0.01(-0.05 to 0.04) | 0.095 |
| Headache | 120U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 0/43 | 1/21 | 0.2 (0.0 to 4.0) | 0.017 | -0.01(-0.07 to 0.04) | 0.032 |
| Headache | 150U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 14/168 | 3/57 | 1.6 (0.5 to 5.9) | 0.109 | 0.01 (-0.03 to 0.06) | 0.075 |
| Headache | 105U-260U (“Follow-the-pain” approach) 24 (three injections at day 0, day 90, and day 180) weeks | Mathew, 200510Low | 12/173 | 11/182 | 1.2 (0.5 to 2.7) | 0.252 | 0.01 (-0.03 to 0.05) | 0.145 |
| Headache | 110U to 260 U per treatment weeks | Aurora, 200715Medium | 11/187 | 9/182 | 1.2 (0.5 to 3.0) | 0.22 | 0.01 (-0.03 to 0.04) | 0.179 |
| Headache | 225U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 15/182 | 3/62 | 1.8 (0.5 to 6.3) | 0.111 | 0.02 (-0.03 to 0.06) | 0.086 |
| Headache | 240U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 0/43 | 1/21 | 0.2 (0.0 to 4.0) | 0.017 | -0.01(-0.07 to 0.04) | 0.032 |
| Headache | All doses | Pooled | 76/1469 | 33/735 | 1.0 (0.5 to 1.6) | 1 | 0.00 (-0.02 to 0.03) | 1 |
| Hypertonia | 75U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 13/174 | 0/59 | 9.9(0.6 to 170.0) | 0.082 | 0.07 (0.04 to 0.10) | 0.179 |
| Hypertonia | 150U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 15/168 | 0/57 | 11.6(0.7 to 197.3) | 0.082 | 0.07 (0.04 to 0.10) | 0.153 |
| Hypertonia | 105U-260U (“Follow-the-pain” approach) 24 (3 injections at day 0, day 90, and day 180) weeks | Mathew, 200510Low | 9/173 | 4/182 | 2.4 (0.7 to 8.1) | 0.461 | 0.05 (0.02 to 0.08) | 0.238 |
| Hypertonia | 110U to 260U per treatment weeks | Aurora, 200715Medium | 13/187 | 2/182 | 6.7 (1.5 to 30.2) | 0.292 | 0.06 (0.04 to 0.09) | 0.236 |
| Hypertonia | 22U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 13/182 | 0/62 | 10.0(0.6 to 170.0) | 0.082 | 0.07 (0.04 to 0.10) | 0.194 |
| **Hypertonia** | **All doses** | **Pooled** | **63/884** | **7/542** | **7.3 (3.1 to 20.9)** | **1** | **0.06 (0.04 to 0.09)** | **1** |
| Neck pain | 75U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 30/174 | 1/59 | 12.1(1.6 to 90.7) | 0.128 | 0.15 (0.09 to 0.21) | 0.13 |
| Neck pain | 120U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 2/43 | 1/21 | 1.0 (0.1 to 11.4) | 0.101 | 0.04 (-0.05 to 0.13) | 0.094 |
| Neck pain | 150 U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 37/168 | 1/57 | 15.8(2.1 to 118.1) | 0.128 | 0.19 (0.12 to 0.25) | 0.125 |
| Neck pain | 105U-260U (“Follow-the-pain” approach) 24 (3 injections at day 0, day 90, and day 180) weeks | Mathew, 200510Low | 23/173 | 1/182 | 27.8(3.7 to 207.9) | 0.128 | 0.13 (0.08 to 0.17) | 0.14 |
| Neck pain | 155U-195U [Follow-the-Pain strategy] 24 (two injections over the course: week 1, week 12; open label 3 injections: week 24, 36, 48) weeks | Aurora, 20101Medium | 20/341 | 0/338 | 43.2(2.6 to 716.7) | 0.085 | 0.06 (0.04 to 0.09) | 0.156 |
| Neck pain | 110U to 260U per treatment weeks | Aurora, 200715Medium | 32/187 | 8/182 | 4.5 (2.0 to 10.0) | 0.233 | 0.13 (0.07 to 0.18) | 0.133 |
| Neck pain | 225U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 41/182 | 1/62 | 17.7(2.4 to 131.9) | 0.128 | 0.19 (0.13 to 0.26) | 0.127 |
| Neck pain | 240U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 0/43 | 1/21 | 0.2 (0.0 to 4.0) | 0.069 | 0.01 (-0.08 to 0.10) | 0.095 |
| **Neck pain** | **All doses** | **Pooled** | **185/1311** | **13/922** | **9.5 (4.7 to 19.2)** | **1** | **0.11 (0.05 to 0.17)** | **1** |
| Neck rigidity | 75U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 14/174 | 0/59 | 10.8(0.6 to 183.1) | 0.061 | 0.08 (0.04 to 0.12) | 0.19 |
| Neck stiffness | 100U 16weeks | Freitag, 20085Low | 1/20 | 1/21 | 1.1 (0.1 to 18.1) | 0.061 | 0.06 (-0.01 to 0.12) | 0.055 |
| Neck rigidity | 150U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 14/168 | 0/57 | 10.8(0.6 to 183.9) | 0.061 | 0.08 (0.04 to 0.12) | 0.185 |
| Neck rigidity | 105U-260U (“Follow-the-pain” approach) 24 (3 injections at day 0, day 90, and day 180) weeks | Mathew, 200510Low | 8/173 | 2/182 | 4.4 (0.9 to 20.8) | 0.201 | 0.04 (0.01 to 0.07) | 0.226 |
| Neck rigidity | 110U to 260U per treatment weeks | Aurora, 200715Medium | 19/187 | 6/182 | 3.3 (1.3 to 8.5) | 0.554 | 0.07 (0.03 to 0.11) | 0.18 |
| Neck rigidity | 225U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 27/182 | 0/62 | 22.1 (1.3 to 368.0) | 0.062 | 0.12 (0.08 to 0.17) | 0.164 |
| **Neck rigidity** | **All doses** | **Pooled** | **83/904** | **10/563** | **6.2 (2.9 to 14.1)** | **1** | **0.08 (0.04 to 0.11)** | **1** |
| Injection site pain | 75U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 8/174 | 3/59 | 0.9 (0.2 to 3.5) | 0.167 | 0.00 (-0.04 to 0.04) | 0.032 |
| Injection site pain | 120U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 0/43 | 1/21 | 0.2 (0.0 to 4.0) | 0.029 | -0.01(-0.05 to 0.04) | 0.011 |
| Injection site pain | 150U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 10/168 | 3/57 | 1.1 (0.3 to 4.3) | 0.176 | 0.00 (-0.04 to 0.04) | 0.029 |
| Injection site pain | 105U-260U (“Follow-the-pain” approach) 24 (3 injections at day 0, day 90, and day 180) weeks | Mathew, 200510Low | 4/173 | 4/182 | 1.1 (0.3 to 4.3) | 0.157 | 0.00 (-0.03 to 0.03) | 0.14 |
| Injection site pain | 110U to 260U per treatment weeks | Aurora, 200715Medium | 4/187 | 1/182 | 4.0 (0.4 to 35.7) | 0.064 | 0.01 (-0.01 to 0.03) | 0.245 |
| Injection site pain | 225U 24 (three injections at day 0, day 90, and day 180) weeks | Silberstein, 20511Low | 17/182 | 3/62 | 2.0 (0.6 to 7.2) | 0.194 | 0.01 (-0.03 to 0.05) | 0.029 |
| Injection site pain | 240U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 0/43 | 1/21 | 0.2 (0.0 to 4.0) | 0.029 | -0.01(-0.05 to 0.04) | 0.011 |
| Pain | 110U to 260U per treatment weeks | Aurora, 200715Medium | 3/187 | 0/182 | 6.9(0.4 to 135.0) | 0.035 | 0.01 (-0.01 to 0.03) | 0.31 |
| Pain | 105U-260U (“Follow-the-pain” approach) 24 (3 injections at day 0, day 90, and day 180) weeks | Mathew, 200510Low | 3/173 | 3/182 | 1.1 (0.2 to 5.3) | 0.119 | 0.00 (-0.02 to 0.02) | 0.185 |
| Pain | 100U 16 weeks | Freitag, 20085Low | 0/20 | 1/21 | 0.3 (0.0 to 8.7) | 0.029 | -0.01(-0.05 to 0.04) | 0.009 |
| **Injection site pain** | **All doses** | **Pooled** | **49/1350** | **20/969** | **1.4 (0.7 to 2.5)** | **1** | **0.00****(-0.02 to 0.02)** | **1** |
| Blepharoptosis | 6U 12 weeks | Saper, 20074Low | 1/45 | 0/11 | 0.8 (0.0 to 20.3) | 0.034 | 0.04 (-0.03 to 0.11) | 0.023 |
| Blepharoptosis | 7.5U 16 weeks | Elkind, 20067Low | 2/105 | 0/36 | 1.8 (0.1 to 37.6) | 0.038 | 0.03 (-0.01 to 0.07) | 0.089 |
| Blepharoptosis | 9U 12 weeks | Saper, 20074Low | 0/49 | 0/12 | 0.3 (0.0 to 13.4) | 0.023 | 0.03 (-0.03 to 0.10) | 0.029 |
| Blepharoptosis | 10U 12 weeks | Saper, 20074Low | 0/44 | 0/11 | 0.3 (0.0 to 13.7) | 0.023 | 0.04 (-0.03 to 0.10) | 0.026 |
| Blepharoptosis | 25U 12 weeks | Saper, 20074Low | 4/49 | 0/12 | 2.5 (0.1 to 49.1) | 0.04 | 0.06 (-0.01 to 0.13) | 0.021 |
| Blepharoptosis | 25U 16 weeks | Elkind, 20067Low | 5/101 | 0/34 | 3.9 (0.2 to 73.0) | 0.042 | 0.05 (0.00 to 0.10) | 0.07 |
| Blepharoptosis | 25U 12 weeks | Silberstein, 20006Medium | 6/42 | 0/21 | 7.7(0.4 to 142.8) | 0.042 | 0.08(0.01 to 0.15) | 0.023 |
| Blepharoptosis | 50U 16 weeks | Elkind, 20067Low | 8/106 | 0/36 | 6.3(0.4 to 111.9) | 0.043 | 0.07 (0.02 to 0.12) | 0.064 |
| Blepharoptosis | 75U 12 weeks | Silberstein, 20006Medium | 7/40 | 0/20 | 9.2(0.5 to 169.4) | 0.042 | 0.09 (0.02 to 0.16) | 0.02 |
| Blepharoptosis | 75U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 6/174 | 1/59 | 2.1 (0.2 to 17.6) | 0.078 | 0.03 (-0.01 to 0.06) | 0.098 |
| Blepharoptosis | 120U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 0/43 | 0/21 | 0.5 (0.0 to 25.8) | 0.023 | 0.02 (-0.03 to 0.08) | 0.057 |
| Blepharoptosis | 150U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 7/168 | 1/57 | 2.4 (0.3 to 20.2) | 0.08 | 0.03 (-0.01 to 0.07) | 0.092 |
| Blepharoptosis | 105U-260U (“Follow-the-pain” approach) 24 (three injections at day 0, day 90, and day 180) weeks | Mathew, 200510Low | 12/173 | 1/182 | 13.5(1.7 to 104.9) | 0.085 | 0.06 (0.03 to 0.10) | 0.104 |
| Blepharoptosis | 110U to 260U per treatment weeks | Aurora, 200715Medium | 29/187 | 3/182 | 11.0(3.3 to 36.6) | 0.246 | 0.11 (0.07 to 0.16) | 0.076 |
| Blepharoptosis | 225U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 12/182 | 1/62 | 4.3 (0.5 to 33.8) | 0.084 | 0.05 (0.01 to 0.09) | 0.088 |
| Blepharoptosis | 240U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 2/43 | 0/21 | 2.6 (0.1 to 56.4) | 0.038 | 0.05 (-0.01 to 0.11) | 0.038 |
| Blepharoptosis | 210U plus 80U 12 (one time injection) weeks | Petri\*, 20099High | 2/64 | 0/63 | 5.1(0.2 to 108.0) | 0.038 | 0.04 (-0.01 to 0.08) | 0.082 |
| **Blepharoptosis** | **All doses** | **Pooled** | **103/1615** | **7/839** | **8.0 (3.5 to 21.6)** | **1** | **0.05 (0.03 to 0.08)** | **1** |
| Muscle weakness | 6U 12 weeks | Saper, 20074Low | 0/45 | 0/11 | 0.3 (0.0 to 13.4) | 0.087 | 0.03 (-0.07 to 0.13) | 0.1 |
| Muscle weakness | 9U 12 weeks | Saper, 20074Low | 0/49 | 0/12 | 0.3 (0.0 to 13.4) | 0.087 | 0.03 (-0.07 to 0.12) | 0.104 |
| Muscle weakness | 10U 12 weeks | Saper, 20074Low | 0/44 | 0/11 | 0.3 (0.0 to 13.7) | 0.087 | 0.03 (-0.07 to 0.13) | 0.1 |
| Muscle weakness | 25U 12 weeks | Saper, 20074Low | 6/49 | 0/12 | 3.7 (0.2 to 71.0) | 0.119 | 0.13 (0.01 to 0.24) | 0.091 |
| Muscle weakness | 75 U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 29/174 | 0/59 | 24.1(1.5 to 401.3) | 0.124 | 0.16 (0.11 to 0.22) | 0.121 |
| Muscle weakness | 150 U 24 (three injections at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 44/168 | 0/57 | 41.1(2.5 to 679.2) | 0.124 | 0.25 (0.18 to 0.32) | 0.118 |
| Muscle weakness | 105U-260U (“Follow-the-pain” approach) 24 (three injections at day 0, day 90, and day 180) weeks | Mathew, 200510Low | 38/173 | 0/182 | 103.7(6.3 to 1703.1) | 0.124 | 0.21 (0.15 to 0.27) | 0.12 |
| Muscle weakness | 155U-195U [Follow-the-Pain strategy] 24 (two injections over the course: week 1, week 12; open label three injections: week 24, 36, 48) weeks | Aurora, 20101Medium | 20/341 | 0/338 | 43.2(2.6 to 716.7) | 0.124 | 0.06 (0.03 to 0.09) | 0.129 |
| Muscle weakness | 225U 24 (three injection at day 0, day 90, and day 180) weeks | Silberstein, 200511Low | 56/182 | 0/62 | 55.8(3.4 to 918.6) | 0.124 | 0.29 (0.22 to 0.36) | 0.118 |
| **Muscle weakness** | **All doses** | **Pooled** | **193/1225** | **1/743** |  |  | **0.13 (0.06 to 0.21)** | **1** |
| Fever | 100U 16 weeks | Freitag, 20085Low | 0/20 | 2/21 | 0.2 (0.0 to 4.2) | 0.059 | -0.05(-0.11 to 0.01) | 0.094 |
| Flu syndrome | 25U 16 weeks | Elkind, 20067Low | 4/101 | 3/34 | 0.4 (0.1 to 2.0) | 0.234 | -0.04(-0.10 to 0.01) | 0.194 |
| Flu syndrome | 50U 16 weeks | Elkind, 20067Low | 7/106 | 3/36 | 0.8 (0.2 to 3.2) | 0.284 | -0.03(-0.09 to 0.02) | 0.197 |
| Flu syndrome | 7.5U 16 weeks | Elkind, 20067Low | 11/105 | 3/36 | 1.3 (0.3 to 4.9) | 0.316 | -0.02(-0.08 to 0.04) | 0.177 |
| Pyrexia | 240U 12 (one time injection) weeks | Chankrachang\*, 20118\*Low | 0/43 | 1/21 | 0.2 (0.0 to 4.0) | 0.054 | -0.04(-0.10 to 0.02) | 0.169 |
| Pyrexia | 120U 12 (one time injection) weeks | Chrankrachang, 20118Low | 0/43 | 1/21 | 0.2 (0.0 to 4.0) | 0.054 | -0.04(-0.10 to 0.02) | 0.169 |
| Pyrexia | All doses | Pooled | 22/418 | 12/169 | 0.5 (0.1 to 1.3) | 1 | -0.04(-0.09 to 0.01) | 1 |

Bold = significant differences at 95% confidence limit when 95% CI of relative measure of the association estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0; CrI = credible intervals; \* trials of abobotulinumtoxinA